|CANCER & TREATMENTS FOR CANCER CENTER PATIENTS PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER|
New director named for U-M breast cancer program
ANN ARBOR, Mich. Â- The University of Michigan Comprehensive Cancer Center announces the appointment of Daniel F. Hayes, M.D., as the new clinical director of its Breast Oncology Program.
Hayes, who also serves as a professor in the Department of Internal Medicine of the U-M Medical School, will be responsible for directing clinical services and overseeing the translation of basic breast cancer research into clinical trials. He comes to the U-M from Georgetown University.
Specifically, Hayes will focus the program's efforts on:
"Dr. Hayes is one the leading experts in developing new treatments for breast cancer patients based on the translation of laboratory science into the clinic," says Max S. Wicha, M.D., director of the U-M Cancer Center and Distinguished Professor of Oncology. "We are delighted to have been able to attract him to Michigan to lead our efforts in this area, helping to further develop what is now one of the strongest breast cancer programs in the nation."
Over nearly 20 years, Hayes' professional training and career have been directed toward bridging the gap between laboratory and clinical research. He received a bachelor's degree (1974) in biology and a master's degree (1977) in biochemistry at Indiana University. He received his M.D. from the Indiana University School of Medicine in 1979, followed by a residency in internal medicine at the University of Texas Health Science Center at Dallas.
Hayes served a fellowship in medical oncology from 1982 to 1985 at Harvard's Dana Farber Cancer Institute (DFCI) in Boston. In 1992, he assumed the role as the medical director of the Breast Evaluation Center at DFCI. In 1996 Hayes moved to Georgetown University and spent the succeeding five years collaborating with Marc E. Lippman, M.D., a world-renowned breast cancer expert who also recently joined the University of Michigan, as chair of the Department of Internal Medicine.
Hayes has been influential in both clinical and laboratory studies of the diagnosis and treatment of breast cancer. With his long-time colleague, Donald Kufe, Hayes published the first reports concerning the development of the CA15-3 blood test, which is currently used worldwide to evaluate patients with breast cancer. He has become an internationally recognized leader in the use of this and other tumor markers, such as HER-2, specifically for breast cancer but also for other cancers. He is widely considered to be an expert in the field of clinical research on breast cancer, particularly in the areas of new hormonal and chemotherapeutic treatments. He also lectures and publishes extensively regarding the management of breast cancer patients.
Reflecting his expertise, Hayes has served as Chair of the Solid Tumor Correlative Sciences Committee of the Cancer and Leukemia Group B (CALGB), one of the leading federally funded, multi-institutional, cooperative groups that perform definitive clinical research in cancer care. He has also been a core member and past vice-chair of the Breast Cancer Committee of the CALGB. He serves on the Expert Panel for Tumor Marker Practice Guidelines for the American Society of Clinical Oncology, and he is on the editorial boards of several leading cancer journals.
Hayes lives in Ann Arbor, Michigan, with his wife Jane and their two sons, Benjamin and Stephen, who are both pursuing post-secondary education.
U-M Comprehensive Cancer Center